Price movement over the last 24 hours
ADMA Biologics Inc vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $63.95. Which is the better fit depends on your goals.
| ADMA | SLVO | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $107.41 |
52-Week Low | $7.60 | $62.46 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
SLVO trades at $68.09, up 1.99% with bearish technical signals from moving averages and mixed oscillators. The stock shows strong momentum indicators with RSI extremes suggesting potential reversal zones. Support and resistance levels cluster tightly around $67-69, indicating critical price decision points ahead.
The technical setup suggests near-term consolidation with bearish momentum prevailing. Investment opportunity exists for contrarian plays at support levels, though risks include the strong bearish technical bias and potential for breakdown below key support. Market sentiment appears cautious pending fundamental clarity.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →